Effect of Oral and Vaginal Hormonal Contraceptives on Inflammatory Blood Biomarkers

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2015 Apr 11

PMID 25861161

Citations 15

Authors

Afshin A Divani

Xianghua Luo

Yvonne H Datta

James D Flaherty

Angela Panoskaltsis-Mortari

Affiliations

Soon will be listed here.

Abstract

The use of combined hormonal contraceptives has been reported to increase the level of C-reactive protein (CRP). We assessed the effect of hormonal contraceptive use on inflammatory cytokines including CRP, monocyte chemotactic protein-1, soluble tumor necrosis factor (sTNF), interleukin-6 (IL-6), and soluble CD40 ligand. We used 79 female subjects (19 to 30 years old) who were combined oral contraceptives users (n = 29), combined vaginal contraceptive users (n = 20), and nonusers (n = 30) with CRP values of ≤1 (n = 46) or ≥3 (n = 33). Information on medical history, physical activities, and dietary and sleeping habits were collected. Both oral and vaginal contraceptive users had higher levels of CRP (P < 0.0001), compared to nonusers. Only oral contraceptive users exhibited elevated sCD40L (P < 0.01). When comparing the groups with CRP ≤ 1 and CRP ≥ 3, levels of IL-6 and sTNF-RI were positively correlated with CRP among oral contraceptive users. We did not observe the same elevation for other inflammatory biomarkers for the CRP ≥ 3 group among vaginal contraceptive users. The clear cause of elevation in CRP level due to the use of different hormonal contraceptive formulations and methods is not well understood. Longitudinal studies with larger sample size are required to better assess the true cause of CRP elevation among hormonal contraceptive users.

Citing Articles

Determinants of new-onset postpartum preeclampsia among mothers who delivered in hospitals in the South Gondar Zone, Northwest Ethiopia: a multicenter case-control study.

Addisu D, Mitiku Y, Yazie Ferede W, Mekuriaw B, Erega B, Bazezew L BMC Pregnancy Childbirth. 2025; 25(1):161.

PMID: 39953424 PMC: 11829449. DOI: 10.1186/s12884-025-07274-z.

Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy.

Yalcinkaya A, Yalcinkaya R, Sardh F, Landegren N Front Immunol. 2025; 15:1501364.

PMID: 39885993 PMC: 11779622. DOI: 10.3389/fimmu.2024.1501364.

Inflammation and Ovarian Function in Reproductive-Aged Women.

Long A, Steiner A, Thompson A, Jahnke H, Harris B, Jukic A Am J Hum Biol. 2024; 37(1):e24196.

PMID: 39623697 PMC: 11671284. DOI: 10.1002/ajhb.24196.

Associations between common contraceptive use and circulating inflammatory biomarkers.

Mongiovi J, Babic A, Sasamoto N, Shafrir A, Huang T, Townsend M Am J Epidemiol. 2024; 194(1):85-94.

PMID: 38896053 PMC: 11735965. DOI: 10.1093/aje/kwae135.

Hormonal contraceptive use is associated with differences in women's inflammatory and psychological reactivity to an acute social stressor.

Mengelkoch S, Gassen J, Slavich G, Hill S Brain Behav Immun. 2023; 115:747-757.

PMID: 37914104 PMC: 11216059. DOI: 10.1016/j.bbi.2023.10.033.

References

Welsh P, Woodward M, Rumley A, Lowe G . Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol. 2008; 141(6):852-61. DOI: 10.1111/j.1365-2141.2008.07133.x. View

Woodward M, Rumley A, Lowe G, Tunstall-Pedoe H . C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 2003; 122(1):135-41. DOI: 10.1046/j.1365-2141.2003.04387.x. View

Norata G, Garlanda C, Catapano A . The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010; 20(2):35-40. DOI: 10.1016/j.tcm.2010.03.005. View

Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires J . Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003; 107(25):3165-9. DOI: 10.1161/01.CIR.0000074208.02226.5E. View

Libby P, Ridker P . Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116 Suppl 6A:9S-16S. DOI: 10.1016/j.amjmed.2004.02.006. View

Li J, Fang C . C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004; 62(4):499-506. DOI: 10.1016/j.mehy.2003.12.014. View

Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350(14):1387-97. DOI: 10.1056/NEJMoa032804. View

Kanda T, Takahashi T . Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004; 45(2):183-93. DOI: 10.1536/jhj.45.183. View

Verma S, Kuliszewski M, Li S, Szmitko P, Zucco L, Wang C . C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109(17):2058-67. DOI: 10.1161/01.CIR.0000127577.63323.24. View

10.

Bassuk S, Rifai N, Ridker P . High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004; 29(8):439-93. View

11.

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

12.

Lagrand W, Visser C, Hermens W, Niessen H, Verheugt F, Wolbink G . C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation. 1999; 100(1):96-102. DOI: 10.1161/01.cir.100.1.96. View

13.

Duijkers I, Killick S, Bigrigg A, Dieben T . A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care. 2005; 9(3):131-40. DOI: 10.1080/13625180400007199. View

14.

Ballantyne C, Nambi V . Markers of inflammation and their clinical significance. Atheroscler Suppl. 2005; 6(2):21-9. DOI: 10.1016/j.atherosclerosissup.2005.02.005. View

15.

Zieske A, Tracy R, McMahan C, Herderick E, Homma S, Malcom G . Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 2005; 25(6):1237-43. DOI: 10.1161/01.ATV.0000164625.93129.64. View

16.

Patel J, Lim H, Nadar S, Tayebjee M, Hughes E, Lip G . Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens. 2005; 24(1):117-21. DOI: 10.1097/01.hjh.0000198034.09010.bc. View

17.

van Rooijen M, Hansson L, Frostegard J, Silveira A, Hamsten A, Bremme K . Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006; 4(1):77-82. DOI: 10.1111/j.1538-7836.2005.01690.x. View

18.

Zhou H, Chen J, Rissanen T, Korrick S, Hu H, Salonen J . Outcome-dependent sampling: an efficient sampling and inference procedure for studies with a continuous outcome. Epidemiology. 2007; 18(4):461-8. PMC: 3664946. DOI: 10.1097/EDE.0b013e31806462d3. View

19.

Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P . Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol. 2007; 27(12):2763-8. DOI: 10.1161/ATVBAHA.107.152777. View

20.

Cauci S, Di Santolo M, Culhane J, Stel G, Gonano F, Guaschino S . Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol. 2008; 111(4):857-64. DOI: 10.1097/AOG.0b013e31816a2476. View